Us Bancorp \De\ Collegium Pharmaceutical, Inc Transaction History

Us Bancorp \De\

$82.9 Billion
Q3 2025

A detailed history of Us Bancorp \De\ transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Us Bancorp \De\ holds 232 shares of COLL stock, worth $10,667. This represents 0.0% of its overall portfolio holdings.

Number of Shares

232

Previous 394 41.12%

Holding current value

$10,667

Previous $11,000 27.27%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$29.75 - $39.59 $4,819 - $6,413	-162 Reduced 41.12%	232 $8,000
Q2 2025 Jul 23, 2025	BUY	$24.67 - $30.44 $4,119 - $5,083	167 Added 73.57%	394 $11,000
Q1 2025 May 08, 2025	BUY	$28.04 - $33.91 $1,822 - $2,204	65 Added 40.12%	227 $6,000
Q2 2024 Aug 06, 2024	BUY	$31.36 - $39.99 $125 - $159	4 Added 2.53%	162 $5,000
Q1 2024 May 07, 2024	BUY	$31.23 - $40.91 $4,934 - $6,463	158 New	158 $6,000

Q2 2023 Aug 09, 2023	SELL	$21.06 - $24.0 $189 - $216	-9 Reduced 10.71%	75 $1,000
Q1 2023 May 09, 2023	BUY	$23.0 - $29.88 $207 - $268	9 Added 12.0%	84 $2,000
Q2 2022 Aug 01, 2022	SELL	$14.22 - $20.88 $4,521 - $6,639	-318 Reduced 80.92%	75 $1,000
Q1 2022 May 11, 2022	BUY	$17.2 - $22.5 $6,759 - $8,842	393 New	393 $8,000
Q3 2021 Nov 10, 2021	SELL	$17.75 - $25.39 $550 - $787	-31 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$21.74 - $25.28 $673 - $783	31 New	31 $1,000
Q1 2019 May 08, 2019	SELL	$13.58 - $18.72 $33,257 - $45,845	-2,449 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$9.3 - $19.14 $22,775 - $46,873	2,449	2,449 $45,000

Others Institutions Holding COLL

# of Institutions

258

Shares Held

37.6M

Call Options Held

53.7K

Put Options Held

200

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.57B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account